Literature DB >> 24506534

Positive Response to Methylprednisolone in a Child with Reactive Lymphoid Hyperplasia of the Conjunctiva.

Agata Brazert1, Anna Gotz-Wieckowska1.   

Abstract

The aim of this paper is to present the case of a child with reactive lymphoid hyperplasia of the conjunctiva, whose lesion regressed completely after oral glucocorticosteroid treatment. The final diagnosis was established on the basis of a histopathological examination combined with an immunohistochemical staining test and the exclusion of other conditions that could generate similar lesions. Because of the lack of general contraindications, methylprednisolone treatment was administered and local improvement was obtained. Reactive lymphoid hyperplasia of the conjunctiva is rarely found in children. It is important to emphasize the fact that lymphoproliferative lesions in the conjunctiva may, on the one hand, represent a lymphoma; on the other hand, they may be caused by a benign lesion-reactive lymphoid hyperplasia of the conjunctiva. Many treatment methods have been reported in the literature on the subject, but there are no clear guidelines concerning therapy in children.

Entities:  

Keywords:  Conjunctival lymphoma; eye; glucocorticosteroids; lymphoproliferative lesions; pediatrics

Mesh:

Substances:

Year:  2014        PMID: 24506534     DOI: 10.3109/08820538.2013.874476

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  2 in total

1.  Topical steroids eye drops in conjunctival reactive lymphoid hyperplasia: Case report.

Authors:  Bernardo Rodrigues Mendes Moraes; Micael Valtoni Dantas do Nascimento; Epitácio Dias da Silva Neto; Ruth Miyuki Santo
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

2.  Bilateral benign reactive lymphoid hyperplasia of the conjunctiva: a case treated with oral doxycycline and review of the literature.

Authors:  Olga Klavdianou; Georgios Kondylis; Vasileios Georgopoulos; Sotiria Palioura
Journal:  Eye Vis (Lond)       Date:  2019-09-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.